Therapy Areas: Diabetes
REGENXBIO reports positive three-year durability data for surabgene lomparvovec in diabetic retinopathy
25 September 2026 - Biotechnology company REGENXBIO Inc (Nasdaq:RGNX) on Thursday announced positive long-term follow-up data from the Phase II ALTITUDE study of investigational surabgene lomparvovec ...
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
24 September 2026 - Life sciences and diagnostics company Revvity Inc (NYSE:RVTY) on Thursday launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solu...
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
22 September 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Tuesday reported positive topline Phase II results for enicepatide, an investigationa...
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
17 September 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Thursday that the US Food and Drug Administration (FDA) has approved Kerendia (finerenone) t...
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
14 September 2026 - Meant Health, a digital health platform that connects patients with licensed clinicians for evaluation, prescription and ongoing care coaching, announced on Saturday that it is exp...
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
9 September 2026 - Life sciences and diagnostics company Revvity Inc (NYSE:RVTY) announced on Wednesday that it has agreed to acquire France-based biotechnology company Human Cell Design (HCD), streng...